Viruses hijack cancer genes to cause leukemia

Viruses hijack cancer genes to cause leukemia

A team of researchers led by Anne Van den Broeke (GIGA-ULg and Institut Jules Bordet-ULB) has uncovered a novel mechanism by which viruses cause leukemia. These new findings, published in Nature Communications, could be key to the understanding of virus induced cancers and the development of targeted therapeutic strategies for a very aggressive type of leukemia.

Approximately 12% of human cancers worldwide are attributed to viral infection. Human T-cell leukaemia Virus-1 (HTLV-1), the first oncogenic retrovirus discovered in human, infects an estimated 20 million people worldwide and causes adult T cell leukemia (ATL), an aggressive leukemia with an extremely poor prognosis. The closely related Bovine Leukemia Virus (BLV) produces a very similar disease in cattle and sheep, with the latter providing a unique outbred animal model for cancer research.

It has been generally assumed that leukemia development is dependent on the production of cancer-promoting agents by the virus yet is independent of the location of the virus within the genome of the cancer cell. The research team was the first to discover that, contrary to the prevailing dogma, HTLV-1 and BLV do not integrate randomly in the host genome but rather in the vicinity of genes involved in cancer (“cancer drivers”). The most surprising observation was that these cancer drivers were systematically positioned upstream relative to the virus rather than downstream as would be expected mechanistically. The team further demonstrated the perturbation of the corresponding genes via interactions with viral “antisense” transcripts (viral factors synthesized in the opposite orientation relative to the classical viral products), revealing a novel mechanism by which oncogenic viruses and antisense transcription contribute to cancer development.

Using novel next generation sequencing (NGS) methods, the researchers further showed that, in both humans and animals, these perturbations are present long before the leukemia becomes aggressive. The screen for finding the precise viral insertion spots in the sheep genome revealed a list of several hundreds of genes, a third of which have not been previously reported in cancer, thus providing a treasure trove of new candidate cancer driver genes for further investigations.

The study, carried out in collaboration with scientists of the Necker University hospital in Paris and the VIDO/Intervac research institute of the University of Saskatchewan in Canada, is the result of interdisciplinary research that combines oncology, viral pathogenesis and animal genomics.

New avenues for cancer research and clinical applications

Having demonstrated the sequestration of host cancer drivers by the virus and the unexpected role of viral antisense transcripts in this process, the team now hopes that further research will be able to identify specific inhibitors as a basis for the future development of targeted therapies. Finally, the NGS method developed in this study can be applied to monitor ATL patients, enabling better prediction of relapse and providing clinicians with a molecular tool to evaluate response to treatment.

Bibliographic information

Nicolas Rosewick, Keith Durkin, Ambroise Marçais, Maria Artesi, Vincent Hahaut, Philip Griebel, Natasa Arsic, Véronique Avettand-Fenoel, Arsène Burny, Carole Charlier, Olivier Hermine, Michel Georges & Anne Van den Broeke (2017)

Cis-perturbation of cancer drivers by the HTLV-1/BLV proviruses is an early determinant of leukemogenesis, Nature Communications, doi: 10.1038/NCOMMS15264

 

Related articles

PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

Liège (Belgium), 21st January 2019. PDC*line Pharma is delighted to announce, that the company is now accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for the Quality Control and Release activities of its anticancer agent PDC*lung, intended for the treatment of patients with lung cancer.  PDC*line Pharma is developing a new

Read more
PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

First Congress in Health Simulation

The Medical Simulation Center of the University of Liège organizes its first congress in Health Simulation: “Towards evidence-based simulation”. Event will be held on Thursday, March 28th, 2019 in the faculty of medicine amphitheatres of Liège University, located on Sart-Tilman campus. Several themes will be discussed: Evidence-based Innovations and advances in simulation Medical education –

Read more
First Congress in Health Simulation

New University Certificate for clinical trials

The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder

Read more
New University Certificate for clinical trials